Abstract:SUMMARY The functional amino group of PEI was used to chemically conjugate doxorubicin (DOX) via pH-sensitive linkage (CA) or pH-insensitive linkage (SA) for pulmonary aerosol co-delivery of DOX and Bcl-2 siRNA. The results showed that CAD-PEI exhibited higher drug release and cytotoxicity in lower pH. Furthermore, tumors in B16F10-implanted mice treated with CADPEI and siRNA were significantly less and lighter than those in non-treatment group. We concluded that CAD-PEI nano-carriers had great potential by pulmonary co-delivery of DOX and gene for the treatment of lung cancer. INTRODUCTION Targeting drug delivery into the lungs has great potential for local drug delivery, presenting several advantages for treating lung cancer, such as high local drug concentration, minimal drug loss, precise quantization and low side effects. Many studies have been studied in the past few years regarding delivering drug or gene to the lungs using nano-carriers for treatment of lung cancer. 3 However, using nano-carriers for pulmonary co-delivery of drug and gene are rarely reported. The objective of this study was to construct co-delivery nano-carriers containing DOX and siRNA, which was expected to treat mice melanoma lung metastasis cancer through pulmonary delivery. The functional amino group of PEI was used to chemically conjugate DOX via pH-sensitive linkage or pH-insensitive linkage to develop CAD-PEI or SAD-PEI conjugates for pulmonary aerosol delivery. The DOX release, cytotoxicity, cellular uptake in vitro and inhibitory activity in vivo were evaluated through pulmonary aerosol delivery. The optimized therapy for melanoma lung metastasis cancer through pulmonary aerosol co-delivery will promote the future development of pulmonary delivery applications. EXPERIMENTAL METHODS The synthesis of the CAD-PEI and SAD-PEI conjugates was prepared by covalent bonding methods. Initially, a certain amount of DOX and cis-aconitic anhydride (CA) or succinic anhydride (SA) were dissolved in anhydrous dimethylformamide (DMF), stirred at room temperature in the dark for 24 h. The products were extracted and CAD (or SAD) was obtained by lyophilization. Afterwards, CAD (or SAD) was dissolved in DMSO, followed by adding NHS and EDC and stirring at room temperature for 12 h. Next, the mixture was added to the PEI hydrochloride solution (pH=7.2~7.4) for reaction for 24 h in the dark. After dialysis, the CAD-PEI or the SAD-PEI conjugate was obtained. H NMR spectra were conducted in D2O at room temperature. In vitro release studies of DOX from conjugates were carried out in phosphate buffer with different pH values. The cytotoxicity were examined in vitro using the MTT assay with different pH values (pH 6.8 and 7.4, respectively). C57BL/6 mice were injected with B16F10 cells to obtain a metastatic lung cancer-bearing animal model. The formations with drug and gene were delivered directly to the lungs in aerosol form using a liquid aerosol device (MicroSprayer® Aerosolizers, Penn-Century,

Pulmonary Codelivery of Doxorubicin and siRNA by pH‐Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer

A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer

Pulmonary Co-delivery of DOX and siRNA

The Suppression Of Metastatic Lung Cancer By Pulmonary Administration Of Polymer Nanoparticles For Co-Delivery Of Doxorubicin And Survivin Sirna

Anti-tumor Effects of Combined Doxorubicin and Sirna for Pulmonary Delivery

Pulmonary co-delivery system for lung tumor treatment

Pulmonary Delivery by Exploiting Doxorubicin and Cisplatin Co-Loaded Nanoparticles for Metastatic Lung Cancer Therapy

Doxorubicin and siRNA Co-Delivery System Based on Carbon Dots Inhibits Metastasis of Lung Cancer by Attenuating Mrp1-Mediated Resistance

EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.

Doxorubicin and Sirna Co-Delivery System Based on Carbon Dots Inhibits Chemoresistance of Lung Cancer Through MRP1

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

Enhanced Lysosomal Escape of pH-Responsive PEI-Betaine Functionalized Carbon Nanotube for the Co-delivery of Survivin siRNA and Doxorubicin.

Stimuli-responsive Nanoparticles for the Codelivery of Chemotherapeutic Agents Doxorubicin and Sipd-L1 to Enhance the Antitumor Effect.

The Promising Nanocarrier for Doxorubicin and Sirna Co-delivery by PDMAEMA-based Amphiphilic Nanomicelles.

Co-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma Model.

Liposome-based Co-Delivery of Sirna and Docetaxel for the Synergistic Treatment of Lung Cancer.

Doxorubicin@Bcl-2 Sirna Core@Shell Nanoparticles for Synergistic Anticancer Chemotherapy.

Co-delivery of Doxorubicin and Afatinib with Ph-Responsive Polymeric Nanovesicle for Enhanced Lung Cancer Therapy

A Nanoplatform Self-Assembled by Coordination Delivers Sirna for Lung Cancer Therapy

Redox-responsive Mesoporous Silica Nanoparticles: a Physiologically Sensitive Codelivery Vehicle for Sirna and Doxorubicin.

Au-siRNA@ Aptamer Nanocages As a High-Efficiency Drug and Gene Delivery System for Targeted Lung Cancer Therapy